touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part Two, click here.
1. What is Gavo-cel and what is its mechanism of action? (00:31-01:37)
2. Could you tell us a little about the dose escalation study you are presenting? (01:37-03:17)
3. What have been the efficacy and safety findings to date? (03:17-07:36)
Disclosures: David Hong has received research (institution) and grant funding (institution) from: AbbVie, Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Deciphera, Eisai, Erasca, Fate Therapeutics, Genentech, Genmab, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, Turning Point Therapeutics, Verstatem and VM Oncology. He has received travel and accommodation expenses from: Bayer, Genmab, AACR, ASCO, SITC and Telperian. He has received consulting, speaker or advisory role fees from: Adaptimmune, Alpha Insights, Acuta, Alkermes, Amgen, Aumbiosciences, Atheneum, Axiom, Barclays, Baxter, Bayer, Boxer Capital, BridgeBio, CDR-life AG, COR2ed, COG, Ecor1, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, Immunogen, Infinity, Janssen, Liberium, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza Therapeutics, Turning Point, WebMD and Ziopharm. He has other ownership interests from: OncoResponse (Founder), Telperian Inc (Advisor).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson
Filmed in coverage of the ESMO 2021 Annual Meeting.
Share this Video
Related Videos In Immunotherapy
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!